OSTEOPOROSIS TREATMENT MARKET ANALYSIS

Osteoporosis Treatment Market, By Drug Type (Bisphosphonates, Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators, Parathyroid Hormone-Related Protein Analog, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In November, 2023, Apotex Inc., a pharmaceutical company, announced that they had launched Teriparatide Injection, a single-patient-use pre-filled pen used for the treatment of osteoporosis in the U.S. Teriparatide Injection is supplied as a single-patient-use pre-filled pen containing 250 mcg/mL, capable of administering 28 daily doses of 20 mcg per pen
In April 2022, the International Osteoporosis Foundation, announced that they had launched LiftOffForBoneHealth, an online public awareness campaign in cooperation with the European Space Agency (ESA)
In August 2021, Enzene Biosciences, a technology driven company based in Pune, India, announced marketing authorization from the Drug Controller General of India (DCGI) for its third biosimilar drug 'Denosumab', indicated for the treatment of osteoporosis in adults
In January 2021, Theramex, a global pharmaceutical company, launched Livogiva, a new teriparatide pre-filled pen for the treatment of severe osteoporosis in Europe.